로그인
보증업체
스포츠중계
스포츠분석
먹튀사이트
지식/노하우
판매의뢰
업체홍보/구인
뉴스
커뮤니티
포토
포인트
보증카지노
보증토토
보증홀덤
스포츠 중계
기타
축구
야구
농구
배구
하키
미식축구
카지노 먹튀
토토 먹튀
먹튀제보
카지노 노하우
토토 노하우
홀덤 노하우
기타 지식/노하우
유용한 사이트
제작판매
제작의뢰
게임
구인
구직
총판
제작업체홍보
실시간뉴스
스포츠뉴스
연예뉴스
IT뉴스
자유게시판
유머★이슈
동영상
연예인
섹시bj
안구정화
출석하기
포인트 랭킹
포인트 마켓
로그인
자동로그인
회원가입
정보찾기
뉴스
더보기
[실시간뉴스]
‘성매매 근절 시민단체 만들더니…’ 유흥업소서 돈 뜯어낸 40대, 징역 5년
N
[연예뉴스]
양치승, '논란' 광장시장 직접갔다 "떡볶이 6개 1인분, 호구 됐나"
N
[연예뉴스]
오두막에 갇힌 두 남자를 둘러싼 진실, 그 재난이 남긴 것들
N
[스포츠뉴스]
임종훈-신유빈, '만리장성' 넘었다...韓 최초 WTT 왕중왕전 혼합복식 초대 챔피언 등극
N
[연예뉴스]
'이강달' 김세정, 1인 2역 이렇게 잘할줄이야..놀라운 감정 폭주
N
커뮤니티
더보기
[자유게시판]
드디어 금요일이군요
[자유게시판]
오늘 다저스 어떻게 생각하시나요
[자유게시판]
하아 댓노
[자유게시판]
식곤증지립니다요
[자유게시판]
벌써 불금이네요
목록
글쓰기
[IT뉴스]Celltrion Posts Record Q2 Results, Accelerates Global Pharma Ambitions
온카뱅크관리자
조회:
44
2025-07-24 11:07:32
<div class="article_view" data-translation-body="true" data-tiara-layer="article_body" data-tiara-action-name="본문이미지확대_클릭"> <section dmcf-sid="VPr3nBnbIY"> <p contents-hash="b9cc231f1230fa1111a48b279bd03715864a3e35142cd3e127bd7ad42e718ae2" dmcf-pid="fQm0LbLKDW" dmcf-ptype="general"> [NA Eun-kyung, Edaily Reporter] Celltrion Co.(KQ:068270) reported record-breaking earnings for the second quarter of 2025, continuing its robust growth trajectory following its highest-ever Q1 results. Fueled by the synergies of a recent merger, improved cost efficiency, and an expanding portfolio of high-margin products, the company is gaining traction in its quest to become a global pharmaceutical leader.</p> <figure class="figure_frm origin_fig" contents-hash="b4dc482b1a0f664816e3873e2eb567850aad8b3af43486bd3283e1a5a3107c84" dmcf-pid="4xspoKo9my" dmcf-ptype="figure"> <p class="link_figure"><img alt="Celltrion R&D scientist (Source: Celltrion)" class="thumb_g_article" data-org-src="https://t1.daumcdn.net/news/202507/24/Edaily/20250724110106052fjvo.jpg" data-org-width="431" dmcf-mid="9BHua2aVEH" dmcf-mtype="image" height="auto" src="https://img3.daumcdn.net/thumb/R658x0.q70/?fname=https://t1.daumcdn.net/news/202507/24/Edaily/20250724110106052fjvo.jpg" width="658"></p> <figcaption class="txt_caption default_figure"> Celltrion R&D scientist (Source: Celltrion) </figcaption> </figure> <p contents-hash="a534b5b1cf2eee3fcd42010e649313fd47ca98acfda6fbbe0bf8e04e0a9b1cf9" dmcf-pid="8MOUg9g2DT" dmcf-ptype="general"><strong>Strong Margins Drive All-Time-High Q2 Earnings</strong></p> <p contents-hash="cfac3332632b94ef3691ccf947391db7b49607620b830e4981dce61e216bbc16" dmcf-pid="6RIua2aVIv" dmcf-ptype="general">According to preliminary figures disclosed by the company, Celltrion logged consolidated revenue of 961.5 billion won ($741 million) and operating profit of 242.5 billion won ($187 million) for the second quarter. Both figures represent record Q2 performance, with revenue up 9.9% and operating profit soaring 234.5% year-over-year. Operating margin improved to the 25% range.</p> <p contents-hash="f0a09cc06df6dfba188b39c3901430567a58b4334af8c916248555a343b3f88e" dmcf-pid="PgW2wxwMmS" dmcf-ptype="general">The company attributed its performance to strong overseas sales of existing biologics and rapid growth in newly launched, high-profit products including Remsima SC (Zymfentra in the U.S.), Yuflyma, Vegzelma, and Steqima. High-margin product sales accounted for 53% of total sales in Q2, up sharply from 30% a year earlier.</p> <p contents-hash="214e0bc9760c27b83e4dacadf3a43041706e42dbcbc8de2739d5bea7e09320d1" dmcf-pid="QaYVrMrRml" dmcf-ptype="general">In addition, sustained efforts to improve manufacturing efficiency contributed to the margin gains. These included the clearance of high-cost inventory carried prior to the merger, increased yields through Titer Improvement(TI), higher utilization at Plant 3, reduced reliance on CDMOs for drug substance production, and the amortization of R&D expenses for legacy products. As a result, the cost of goods sold ratio fell to approximately 43% in Q2 from 58% a year earlier, with a 4 percentage point improvement from Q1 alone.</p> <p contents-hash="33a206f2aa02b7a1f25264e1cf6233cc421252f72ba4a1317e374ec5d9eb484f" dmcf-pid="xNGfmRmeEh" dmcf-ptype="general"><strong>Four New Products Slated for H2 Launch</strong></p> <p contents-hash="dda20d8800bcf3ef54313f54b80ef89b71616f6a3ddd3a8519f92eb5ed60b4cf" dmcf-pid="y0eCKYKGrC" dmcf-ptype="general">Building on its H1 momentum, Celltrion aims to ramp up growth in the second half with multiple new product launches. The company plans to roll out four new biosimilars Omliclo, Aptozma, Idenzelt, and Stoboclo-Ocenbelt in major global markets by year-end.</p> <p contents-hash="a82c1f55a5a16d65a57611e01acc0ae83853603fce6bff35074a2fe976e1da69" dmcf-pid="Wpdh9G9HDI" dmcf-ptype="general">Having already achieved its initial goal of building an 11-product portfolio by 2025, Celltrion now targets a total of 22 biosimilars by 2030. Its next-generation pipeline includes biosimilar versions of Ocrevus, Cosentyx, Keytruda, and Darzalex all currently in development.</p> <p contents-hash="a3d69cc8eb696658aa4fcaeeca22396e52d7d7b9ce73e6ca28645d9e7bd1ffc4" dmcf-pid="YUJl2H2XmO" dmcf-ptype="general">In parallel, Celltrion is expanding its innovative drug portfolio, focusing on next-generation modalities such as antibody-drug conjugates (ADCs) and multispecific antibodies. Four novel drug candidates are set to enter Phase 1 trials this year. The company plans to file INDs for 13 assets including nine ADCs and four multispecifics by 2028.</p> <p contents-hash="c26de366d490697c077660f80d639631b46517fc0c2358896ef0bd8c40ce2017" dmcf-pid="GuiSVXVZss" dmcf-ptype="general"><strong>Analyst Confidence Grows on Earnings Visibility</strong></p> <p contents-hash="a2ee3485d7b4db1a240c6ec0ee64ab4e964a1f3a348bfb57ee3b110ba6977e7e" dmcf-pid="H7nvfZf5rm" dmcf-ptype="general">Analysts expressed confidence in Celltrion’s long-term trajectory. “The sharp increase in high-margin product sales and internalization of drug substance production helped enhance profitability,” said Seo Geun-hee, team leader at Samsung Securities. “With four new launches scheduled for H2, we expect the growth momentum to continue.”</p> <p contents-hash="35f212b2a8d59f86c9dc05d3b0baddfaa636f543d466fbef1fe3ba4fe94dabdf" dmcf-pid="XzLT4541Er" dmcf-ptype="general">Kwon Hae-soon of Eugene Investment & Securities noted the company’s unusual timing in announcing its Q2 results earlier than expected. “This suggests confidence in its earnings performance and a proactive effort to reduce market uncertainty,” she said.</p> <p contents-hash="7bba66c8e4975e30b337f9ad7c0d1d5e67723810ecb6c449ef6443edf918ec95" dmcf-pid="ZKNGQ3Q0Iw" dmcf-ptype="general">Han Seung-yeon of NH Investment & Securities pointed to sustained margin improvements ahead, citing the planned transition to in-house TI production and the completion of Remsima R&D amortization. “New launches such as Omliclo and Aptozma will reinforce top-line growth, while cost efficiency measures will continue to strengthen margins,” he said.</p> <p contents-hash="8cc4fa63d5a06b1a297156252d25f0a4408111bfcde9406ec2d25a890f83bc35" dmcf-pid="59jHx0xpsD" dmcf-ptype="general">A Celltrion spokesperson emphasized, “The record Q2 results reflect the success of our high-margin product strategy and ongoing cost improvements. We are committed to leveraging these gains to expand our global presence through continuous innovation and market expansion.”</p> <p contents-hash="3455d7e2bfaffb7c5aae6b853eeb85d499faaf9e6fcb285c5f87f97566e12f8d" dmcf-pid="12AXMpMUsE" dmcf-ptype="general">The company reiterated its ambition to establish itself as a top-tier global pharmaceutical company, pledging further investment in R&D and global commercialization efforts in the coming years.</p> <figure class="figure_frm origin_fig" contents-hash="52483a15268e585156b4616663e9a9cfd3a45264e73af173a84be17301b5b7e5" dmcf-pid="tVcZRURurk" dmcf-ptype="figure"> <p class="link_figure"><img class="thumb_g_article" data-org-src="https://t1.daumcdn.net/news/202507/24/Edaily/20250724110107437kiev.jpg" data-org-width="420" dmcf-mid="21uiYAYcsG" dmcf-mtype="image" height="auto" src="https://img3.daumcdn.net/thumb/R658x0.q70/?fname=https://t1.daumcdn.net/news/202507/24/Edaily/20250724110107437kiev.jpg" width="658"></p> </figure> <p contents-hash="75183802573dc31dae5d44f87d3c47919cafbc5c8ecc08774300dc07932fbbf8" dmcf-pid="Ffk5eue7rc" dmcf-ptype="general">나은경 (eeee@edaily.co.kr) </p> </section> </div> <p class="" data-translation="true">Copyright © 이데일리. 무단전재 및 재배포 금지.</p>
댓글등록
댓글 총
0
개
맨위로
이번주
포인트
랭킹
매주 일요일 밤 0시에 랭킹을 초기화합니다.
1
4,000
상품권
2
3,000
상품권
3
2,000
상품권
업체홍보/구인
더보기
[구인]
유투브 BJ 구인중이자나!완전 럭키비키자나!
[구인]
에카벳에서 최대 조건으로 부본사 및 회원님들 모집합니다
[구인]
카지노 1번 총판 코드 내립니다.
[구인]
어느날 부본사 총판 파트너 모집합니다.
[구인]
고액전용 카지노 / 헬렌카지노 파트너 개인 팀 단위 모집중 최고우대
지식/노하우
더보기
[카지노 노하우]
혜택 트렌드 변화 위험성 다시 가늠해 보기
[카지노 노하우]
호기심이 부른 화 종목 선택의 중요성
[카지노 노하우]
카지노 블랙잭 카드 조합으로 히트와 스탠드를 결정하는 방법
[카지노 노하우]
흥부가 놀부될때까지 7
[카지노 노하우]
5월 마틴하면서 느낀점
판매의뢰
더보기
[제작판매]
html5웹미니게임제작 해시게임제작 카드포커게임제작 스포츠토토 카지노 슬롯 에볼루션 토지노 솔루션분양임대재작
[제작판매]
html5웹미니게임제작 해시게임제작 카드포커게임제작 스포츠토토 카지노 슬롯 에볼루션 토지노 솔루션분양임대재작
[제작판매]
html5웹미니게임제작 해시게임제작 카드포커게임제작 스포츠토토 카지노 슬롯 에볼루션 토지노 솔루션분양임대재작
[제작판매]
html5웹미니게임제작 해시게임제작 카드포커게임제작 스포츠토토 카지노 슬롯 에볼루션 토지노 솔루션분양임대재작
[제작판매]
html5웹미니게임제작 해시게임제작 카드포커게임제작 스포츠토토 카지노 슬롯 에볼루션 토지노 솔루션분양임대재작
포토
더보기
채팅하기